Suppr超能文献

接受血液透析患者整合药学服务相关的临床结局:质量改进报告。

Clinical outcomes associated with receipt of integrated pharmacy services by hemodialysis patients: a quality improvement report.

机构信息

Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN 55404, USA.

出版信息

Am J Kidney Dis. 2013 Sep;62(3):557-67. doi: 10.1053/j.ajkd.2013.02.360. Epub 2013 Apr 16.

Abstract

BACKGROUND

Reducing medication-related problems and improving medication adherence in hemodialysis patients may improve clinical outcomes. In 2005, a large US dialysis organization created an integrated pharmacy program for its patients. We aimed to compare the outcomes of hemodialysis patients enrolled in this program and matched control patients.

STUDY DESIGN

Quality improvement report.

SETTING & PARTICIPANTS: Hemodialysis patients with concurrent Medicare and Medicaid eligibility who chose to receive program services and propensity score-matched controls; the propensity score was an estimated function of demographic characteristics, comorbid conditions, medication exposure, serum concentrations, and vascular access method.

QUALITY IMPROVEMENT PLAN

Program services included medication delivery, refill management, medication list reviews, telephonic medication therapy management, and prior authorization assistance.

OUTCOMES

Relative rates of death and hospitalization.

MEASUREMENTS

Survival estimates calculated with the Kaplan-Meier method; mortality hazards compared with Cox regression; hospitalization rates compared with Poisson regression.

RESULTS

In outcome models, there were 8,864 patients receiving integrated pharmacy services and 43,013 matched controls. In intention-to-treat and as-treated analyses, mortality HRs for patients receiving integrated pharmacy services versus matched controls were 0.92 (95% CI, 0.86-0.97) and 0.79 (95% CI, 0.74-0.84), respectively. Corresponding relative rates of hospital admissions were 0.98 (95% CI, 0.95-1.01) and 0.93 (95% CI, 0.90-0.96), respectively, and of hospital days, 0.94 (95% CI, 0.90-0.98) and 0.86 (95% CI, 0.82-0.90), respectively. Cumulative incidences of disenrollment from the pharmacy program were 23.4% at 12 months and 37.0% at 24 months.

LIMITATIONS

Patients were not randomly assigned to receive integrated pharmacy services; as-treated analyses may be biased because of informative censoring by disenrollment from the pharmacy program; data regarding use of integrated pharmacy services were lacking.

CONCLUSIONS

Receipt of integrated pharmacy services was associated with lower rates of death and hospitalization in hemodialysis patients with concurrent Medicare and Medicaid eligibility. Studies are needed to measure pharmacy program use and assess detailed clinical and economic outcomes.

摘要

背景

减少与药物相关的问题并提高血液透析患者的用药依从性可能会改善临床结果。2005 年,一家大型美国透析机构为其患者创建了一个综合药房计划。我们旨在比较参与该计划的血液透析患者和匹配对照患者的结局。

研究设计

质量改进报告。

设置和参与者

同时符合医疗保险和医疗补助资格的血液透析患者选择接受计划服务和倾向评分匹配的对照患者;倾向评分是根据人口统计学特征、合并症、药物暴露、血清浓度和血管通路方法的估计函数。

质量改进计划

计划服务包括药物输送、续药管理、药物清单审查、电话药物治疗管理和事先授权协助。

结果

死亡率和住院率的相对比率。

测量

使用 Kaplan-Meier 方法计算生存估计值;使用 Cox 回归比较死亡率风险;使用泊松回归比较住院率。

结果

在结局模型中,有 8864 名患者接受了综合药房服务,有 43013 名匹配对照。在意向治疗和实际治疗分析中,接受综合药房服务的患者与匹配对照的死亡率 HR 分别为 0.92(95%CI,0.86-0.97)和 0.79(95%CI,0.74-0.84)。相应的相对入院率分别为 0.98(95%CI,0.95-1.01)和 0.93(95%CI,0.90-0.96),相应的住院天数分别为 0.94(95%CI,0.90-0.98)和 0.86(95%CI,0.82-0.90)。药房计划的失约累积发生率在 12 个月时为 23.4%,在 24 个月时为 37.0%。

局限性

患者未随机分配接受综合药房服务;实际治疗分析可能因药房计划失约而导致信息偏倚;缺乏关于综合药房服务使用的数据。

结论

同时符合医疗保险和医疗补助资格的血液透析患者接受综合药房服务与死亡率和住院率降低相关。需要研究来衡量药房计划的使用情况,并评估详细的临床和经济结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验